Bioadhesive Hyaluronic Acid/Dopamine Hydrogels for Vascular Applications Prepared by Initiator-Free Crosslinking.

atorvastatin bioadhesion hyaluronic acid hydrogel initiator-free crosslinking mussel inspired polymers perivascular administration

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
20 May 2022
Historique:
received: 28 04 2022
revised: 16 05 2022
accepted: 17 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

Intimal hyperplasia, a vascular pathology characterized by vessel wall thickening, is implicated in vein graft failures. For efficient prevention, a biodegradable drug delivery system should be applied externally to the graft for an extended time. Finding a gel suitable for such a system is challenging. We have synthesized HA-Dopamine conjugates (HA-Dop) with several degrees of substitution (DS) and used two crosslinking methods: initiator-free crosslinking by basic pH shift or commonly used crosslinking by a strong oxidizer, sodium periodate. The rheological properties, bioadhesion to vascular tissue, cytocompatibility with fibroblasts have been compared for both methods. Our results suggest that initiator-free crosslinking provides HA-Dop gels with more adequate properties with regards to vascular application than crosslinking by strong oxidizer. We have also established the cytocompatibility of the initiator-free crosslinked HA-Dop gels and the cytotoxicity of dopamine-sodium periodate combinations. Furthermore, we have incorporated a drug with anti-restenotic effect in perivascular application, atorvastatin, into the gel, which showed adequate release profile for intimal hyperplasia prevention. The oxidizer-free formulation with improved bioadhesion holds promise as an efficient and safe drug delivery system for vascular applications.

Identifiants

pubmed: 35628516
pii: ijms23105706
doi: 10.3390/ijms23105706
pmc: PMC9146728
pii:
doi:

Substances chimiques

Biocompatible Materials 0
Cross-Linking Reagents 0
Hydrogels 0
Hyaluronic Acid 9004-61-9
Dopamine VTD58H1Z2X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Drug Deliv. 2018 Nov;25(1):766-772
pubmed: 29536778
Chem Res Toxicol. 2017 Jan 17;30(1):13-37
pubmed: 27617882
Plast Reconstr Surg. 2007 Nov;120(6 Suppl):41S-54S
pubmed: 18090342
Colloids Surf B Biointerfaces. 2020 Dec;196:111279
pubmed: 32750605
J Control Release. 2016 Jul 10;233:174-80
pubmed: 27179635
J Control Release. 2016 Jun 28;232:93-102
pubmed: 27091698
J Mater Chem B. 2018 Oct 21;6(39):6234-6244
pubmed: 32254614
J Pharm Pharm Sci. 2015;18(1):53-60
pubmed: 25877441
Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109835
pubmed: 31349495
Acta Biomater. 2019 Jan 1;83:314-321
pubmed: 30423432
Biomacromolecules. 2017 Jul 10;18(7):2205-2213
pubmed: 28613846
J Am Coll Cardiol. 2004 Dec 7;44(11):2149-56
pubmed: 15582312
Biomaterials. 2017 Jun;128:56-68
pubmed: 28288349
Pharmacol Ther. 2022 Jul;235:108157
pubmed: 35183591
Biomater Sci. 2018 Jan 30;6(2):332-339
pubmed: 29265138
Colloids Surf B Biointerfaces. 2019 Oct 1;182:110388
pubmed: 31369955
J Tissue Eng. 2016 Dec 17;7:2041731416683745
pubmed: 28228930
Oral Oncol. 2010 Sep;46(9):698-704
pubmed: 20729136
J Polym Sci A Polym Chem. 2017 Jan 1;55(1):9-33
pubmed: 27917020
J Vasc Surg. 2015 Jan;61(1):203-16
pubmed: 24095042
J Vasc Surg. 2017 Jan;65(1):207-217.e3
pubmed: 27034112
Biomacromolecules. 2016 Jun 13;17(6):1939-48
pubmed: 27112904

Auteurs

Tamara Melnik (T)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.

Senda Ben Ameur (S)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.

Nasreddine Kanfar (N)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.

Laurent Vinet (L)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
Service of Vascular Surgery, Department of Heart and Vessels, University Hospital, Rue du Bugnon 36, 1011 Lausanne, Switzerland.

Florence Delie (F)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.

Olivier Jordan (O)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH